These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 10613996

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ, Jordan RE, Mascelli MA.
    Thromb Haemost; 2001 Mar 17; 85(3):539-43. PubMed ID: 11307828
    [Abstract] [Full Text] [Related]

  • 6. IIb's are not IIb's.
    Kereiakes DJ, Runyon JP, Broderick TM, Shimshak TM.
    Am J Cardiol; 2000 Apr 27; 85(8A):23C-31C. PubMed ID: 10793177
    [Abstract] [Full Text] [Related]

  • 7. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
    Nakada MT, Sassoli PM, Tam SH, Nedelman MA, Jordan RE, Kereiakes DJ.
    J Thromb Thrombolysis; 2002 Aug 27; 14(1):15-24. PubMed ID: 12652146
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.
    Kereiakes DJ, Lorenz T, Young JJ, Kukielka G, Mueller MN, Nanniazzi-Alaimo L, Phillips DR.
    J Thromb Thrombolysis; 2001 Oct 27; 12(2):123-7. PubMed ID: 11729363
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.
    Moser M, Bertram U, Peter K, Bode C, Ruef J.
    J Cardiovasc Pharmacol; 2003 Apr 27; 41(4):586-92. PubMed ID: 12658060
    [Abstract] [Full Text] [Related]

  • 12. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE.
    Am J Cardiol; 1999 May 06; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract] [Full Text] [Related]

  • 13. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
    Goto S, Tamura N, Li M, Handa M, Ikeda Y, Handa S, Ruggeri ZM.
    J Thromb Haemost; 2003 Sep 06; 1(9):2022-30. PubMed ID: 12941046
    [Abstract] [Full Text] [Related]

  • 14. Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.
    Lev EI, Osende JI, Richard MF, Robbins JA, Delfin JA, Rodriguez O, Sharma SK, Jayasundera T, Badimon JJ, Marmur JD.
    J Am Coll Cardiol; 2001 Mar 01; 37(3):847-55. PubMed ID: 11693761
    [Abstract] [Full Text] [Related]

  • 15. Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials.
    Chew DP, Bhatt DL.
    Intern Med J; 2002 Jul 01; 32(7):338-45. PubMed ID: 12088354
    [Abstract] [Full Text] [Related]

  • 16. Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond.
    Giordano A, Musumeci G, D'Angelillo A, Rossini R, Zoccai GB, Messina S, Coscioni E, Romano S, Romano MF.
    Curr Drug Metab; 2016 Jul 01; 17(2):194-203. PubMed ID: 26652157
    [Abstract] [Full Text] [Related]

  • 17. Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
    Mansur Ade P, Roggerio A, Takada JY, Caribé PM, Avakian SD, Strunz CM.
    Sao Paulo Med J; 2016 Jan 19; 134(3):199-204. PubMed ID: 26786608
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
    Li Y, Spencer FA, Ball S, Becker RC.
    J Thromb Thrombolysis; 2000 Aug 19; 10(1):69-76. PubMed ID: 10947916
    [Abstract] [Full Text] [Related]

  • 19. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation.
    Frelinger AL, Furman MI, Barnard MR, Krueger LA, Dae MW, Michelson AD.
    Am J Cardiol; 2003 Nov 01; 92(9):1099-101. PubMed ID: 14583364
    [Abstract] [Full Text] [Related]

  • 20. [Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].
    Schrör K.
    Herz; 2001 Apr 01; 26 Suppl 1():30-5. PubMed ID: 11349624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.